Tai'ai (telitacicept) / Rongchang Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   1 News 


«12345»
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Enrollment closed, Enrollment change, Trial primary completion date:  A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy (clinicaltrials.gov) -  Aug 30, 2023   
    P2,  N=15, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=30 --> 15 | Trial primary completion date: Jul 2023 --> Feb 2024
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Clinical, P2 data, Journal:  Efficacy and safety of telitacicept in primary Sj (Pubmed Central) -  Jul 3, 2023   
    P2
    No abstract available Telitacicept showed clinical benefits and well tolerance and safety in the treatment of pSS.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Review, Journal:  Telitacicept for autoimmune nephropathy. (Pubmed Central) -  Jun 25, 2023   
    In this review, we explored telitacicept's mechanism of action and clinical data. In addition, the immune features of autoimmune nephropathy were discussed, emphasizing lupus nephritis, IgA nephropathy, and membranous nephropathy.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    New P4 trial:  Efficacy and Safety of Telitacicept in Early SLE (clinicaltrials.gov) -  Jun 12, 2023   
    P4,  N=180, Recruiting, 
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Phase classification, Enrollment change:  Study of Telitacicept in Patients With Refractory IgA Nephropathy (clinicaltrials.gov) -  Feb 24, 2023   
    P2/3,  N=40, Not yet recruiting, 
    This effect is indicative of a reduced risk for future kidney disease progression. Phase classification: P3 --> P2/3 | N=182 --> 40
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Journal:  γ-Core Guided Antibiotic Design Based on Human Enteric Defensin 5. (Pubmed Central) -  Jan 22, 2023   
    Molecular dynamics simulation revealed that five Arg residues, Arg1, Arg7, Arg9, Arg15, and Arg18, mediated most of the polar interactions of RC18 with the phospholipid head groups during membrane penetration. In vivo experiments indicated that RC18 decreased MRSA colonization and dramatically improved the survival of infected mice, thus demonstrating that RC18 is a promising drug candidate to treat MRSA infections.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    New P2 trial:  A Study of Telitacicept in Lupus Nephritis (clinicaltrials.gov) -  Jan 11, 2023   
    P2,  N=120, Not yet recruiting, 
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Trial completion date, Trial primary completion date:  A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy (clinicaltrials.gov) -  Dec 22, 2022   
    P2,  N=30, Recruiting, 
    In vivo experiments indicated that RC18 decreased MRSA colonization and dramatically improved the survival of infected mice, thus demonstrating that RC18 is a promising drug candidate to treat MRSA infections. Trial completion date: Sep 2022 --> Jan 2024 | Trial primary completion date: Aug 2022 --> Jul 2023
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma, Sutent (sunitinib) / Pfizer
    METABOLITES COULD BE PROGNOSTIC BIOMARKERS AND POTENTIAL DRUG TARGETS FOR ADVANCED RENAL-CELL CARCINOMA (Sapphire ABEFIJMN) -  Nov 20, 2022 - Abstract #SUO2022SUO_261;    
    Feasible ways of targeting these metabolites include stimulating or inhibiting upstream enzymes of them. The development of drug combinations that can simultaneously target tumor cells, immune cells and the metabolites in the microenvironment may represent a solution to increase therapeutic response.
  • ||||||||||  Clinical, Journal:  B cell depletion and inhibition in systemic lupus erythematosus. (Pubmed Central) -  Nov 8, 2022   
    However, after more than two decades of research and over 40 randomized clinical trials, only one such therapy, belimumab, has been approved for use in SLE...Despite a lack of supporting phase III evidence, rituximab is used off-label in SLE...Successful phase II trials have recently been reported for obinutuzumab and telitacicept with larger confirmatory trials currently underway. Refinements in pharmaceutical mechanisms of action, trial design, and patient selection have resulted in recent preliminary successes, offering renewed optimism for B-cell targeted therapeutics in SLE management.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Journal:  Curtobacterium, A Foliar Pathogen Isolated from Maize in Central Argentina. (Pubmed Central) -  Jul 23, 2022   
    Two strains (RC18-1/2 and RC18-3/1) were selected for further studies...To our knowledge, this study provides the first evidence about the isolation of a Curtobacterium pathogenic strain in maize. Effective crop disease management will require the use of integrated strategies, such as resistant cultivars and/or biocontrol agents.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    THE BIOLOGICAL FUNCTION AND MECHANISM EXPLORATION OF TACI IN SJOGREN’S SYNDROME () -  May 24, 2022 - Abstract #EULAR2022EULAR_3042;    
    The expression of TACI on peripheral blood B cells was deficient in pSS patients. TACI deficiency was closely associated with the downregulation of hsa-miR-30b-5p, activating TGF-β/Hippo pathway mediated by its target gene SMAD1 and taking part in the pathogenesis of pSS.
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Enrollment open:  Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus (clinicaltrials.gov) -  May 23, 2022   
    P1,  N=75, Recruiting, 
    TACI deficiency was closely associated with the downregulation of hsa-miR-30b-5p, activating TGF-β/Hippo pathway mediated by its target gene SMAD1 and taking part in the pathogenesis of pSS. Not yet recruiting --> Recruiting